Alpha-tocopheryloxyacetic acid (alpha-TEA) is an inducer of cancer cell apoptosis pathway. Alpha-tocopheryloxyacetic acid is promising for research of solid and hematological malignancies.

ALM-201 is a peptide inhibitor of angiogenesis targeting microtubule. ALM-201 can inhibit cells migration, tubule formation and microvessel formation. ALM-201 can be used for the research of cancer.

ALK-IN-35 is a ALK degrader with an IC50 of 0.74 nM. ALK-IN-35 inhibits ALK kinase activity, increases the solvent-accessible surface area of hydrophobic residues near the ALK binding pocket, promotes ALK to form a partially unfolded conformation, and induces proteasomal degradation of ALK. ALK-IN-35 inhibits cancer cell proliferation. ALK-IN-35 can be used in research related to non-small cell lung cancer.

ALK-IN-24 is an orally active ALK inhibitor with an IC50 value of 1.7 nM. ALK-IN-24 also inhibits insulin receptor kinase with an IC50 value of 6 nM. ALK-IN-24 suppresses the proliferation of lung adenocarcinoma cells. ALK-IN-24 inhibits ALK-driven tumor growth in xenograft mouse models. ALK-IN-24 can be used in research related to non-small cell lung cancer.

Alixorexton (ALKS 2680) enantiomer is the enantiomer of Alixorexton. Alixorexton is a selective, orally active and brain-penetrant agonist for orexin-2 receptor and can be used for hypersomnias research.

Alinastine is a new antihistamine agent.

Alimadol is an orally active opioid receptor agonist with analgesic activity. Alimadol can be used for the research of pain.

AldoView precursor-1 (Compound 7) is the key labeling precursor for the synthetic radioactive PET tracer [18F] AldoView. [18F] AldoView is a selective aldosterone synthase PET tracer used for imaging in primary hyperaldosteronism.

AldoView (Compound 3) is an intermediate. AldoView can be labeled with fluorine-18 to synthesize [18F]AldoView. [18F]AldoView is a highly selective aldosterone synthase PET imaging agent. AldoView can be used in imaging studies of primary aldosteronism.

ALDH3A1-IN-4 is a selective ALDH3A1 inhibitor with an IC50 of 0.2 μM. ALDH3A1-IN-4 binds to the aldehyde-binding pocket of ALDH3A1 via hydrophobic interactions and van der Waals forces. ALDH3A1-IN-4 acts as a chemosensitizer that sensitizes ALDH3A1-expressing cancer cells to the antiproliferative effect of mafosfamide, but does not produce a sensitizing effect on non-cancer cells that do not express ALDH3A1. ALDH3A1-IN-4 is applicable to research related to lung adenocarcinoma and glioblastoma.

ALC1-IN-1 (compound 1) is an ALC1 inhibitor in crystalline form that can be used in the research of cancer.

Ala-Ala-Ala-NH-CH2OCH2COOH (Compound 37p) is a ADC linker, which serves as an intermediate for ADC synthesis.

AL-38022A is a potent and selective 5-HT2 receptor agonist (Ki ≤2.2 nM), but a significantly lower (>100-fold less) affinity for other 5-HT receptors. AL-38022A potently stimulates functional responses via 5-HT2 receptor subtypes including [Ca2+]i mobilization and tissue contractions with apparently similar potencies and intrinsic activities. AL-38022A fully generalizes to the (±)-1-(2,5-dimethoxy 4-methylphenyl)-2-aminopropane hydrochloride (DOM) stimulus in drug discrimination paradigms. AL-38022A can be used for the glaucoma research.

AL-321 is an insulin sensitizer. AL-321 exhibits significant hypoglycemic and hypolipidemic activities in insulin resistance models. AL-321 can be used in the research of hereditary obesity-related diabetes.

Akt3 ligand-1 is an Akt3 inhibitor (IC50 = 0.1 nM) and a ligand for the target protein for PROTAC (Akt3). Akt3 ligand-1 can be used to synthesize PROTAC Akt3 Degrader-1.

AKT1-IN-11, a Podophyllotoxin derivative, is a AKT1/tubulin dual inhibitor. AKT1-IN-11 down-regulates the phosphorylation level of AKT kinase in tumor cells, disrupting cell proliferation, causeing G2/M phase arrest and inducing apoptosis. AKT1-IN-11 also promotes tubulin depolymerization. AKT1-IN-11 can be used for the research of colorectal cancer.

AK177 is an allosteric activator of IRE1α ribonuclease, with values of 480 nM and 180 nM against non-phosphorylated and phosphorylated IRE1α, respectively.\n

AJ-3941 is an orally active cerebrovascular-selective Calcium Channel antagonist having anti-lipid peroxidative action. AJ-3941 can ameliorate the brain infarction and edema after permanent focal cerebral ischemia.

AI 3-25755 (OMS-403) is a peroxisome proliferator-activated receptor gamma (PPARγ) agonist. AI 3-25755 can be used for research on opioid abuse and smoking cessation.

AgrC-IN-1 is an AgrC inhibitor with an IC50 of 3.5 μM against Staphylococcus aureus AgrC. AgrC-IN-1 competitively binds to AgrC, inhibiting its autophosphorylation activity in Staphylococcus aureus. AgrC-IN-1 inhibits quorum sensing in Staphylococcus aureus, blocking virulence factor production. AgrC-IN-1 can be used for the research of Staphylococcus aureus infections.

AGN-191659 is an orally active RAR/RXR agonist with EC50 values of 11 nM, 23 nM, and 37 nM for RXRα, RARβ, and RARγ, respectively. AGN-191659 activates RXRα, RARβ and RARγ to induce gene transcription. AGN-191659 induces tissue transglutaminase activity, inhibits ornithine decarboxylase activity induced by tumor promoters, and suppresses chondrogenesis. AGN-191659 reverses basic fibroblast growth factor-induced endothelial cell proliferation. AGN-191659 induces hypertriglyceridemia in rat models. AGN-191659 inhibits total heparin-releasable lipase activity. AGN-191659 can be used in research related to promyelocytic leukemia and hypertriglyceridemia.

AGN-190383 is a bee venom phospholipase A2 inhibitor. AGN 190383 inhibits both hormone-operated and depolarization-dependent calcium mobilization as well as fMLP stimulated increases in free cytosolic calcium. AGN-190383 has anti-inflammatory activity.

AGN 192403 (BRD4780) is a potent and selective imidazoline-1 receptor antagonist with a Ki value of 42 nM. AGN 192403 is also a TMED9 inhibitor. AGN 192403 shows protective effects on oxidative cytotoxicity and mitochondrial inhibitor-induced cytotoxicity in astrocytes. AGN 192403 mitigates the proliferation and migration of differentiated glioma tumor cells. AGN 192403 can be used for glioma tumor and neurological diseases research.

AG-024104 is a CDK inhibitor with Ki values of 2.3 nM (CDK1/cyclinB), 1.8 nM (CDK2/cyclinA), and 0.67 nM (CDK4/cyclinD). AG-024104 functionally inhibits kinase activity of CDK1/cyclinB, CDK2/cyclinA, and CDK4/cyclinD. AG-024104 serves as a negative control for peripheral leukocyte toxicity studies in preclinical development.

AFP464 (NSC710464) is a prodrug of Aminoflavone and an agonist of the aryl hydrocarbon receptor (AhR). AFP464 downregulates the expression of α6-integrin (α6-integrin), inhibits breast tumor growth, reduces the population of tumor-initiating cells, disrupts mammosphere structure, induces the formation of mucin lake clusters, triggers DNA damage, and exerts antiproliferative activity. AFP464 is rapidly converted to Aminoflavone by nonspecific esterases in plasma and cell culture media. AFP464 is applicable to research related to breast cancer.

Aescigenin is a triterpenoid saponin compound that can be found in Aesculus hippocastanum. Aescigenin is the main component of sodium β-aescin, a compound that has the functions of reducing tissue edema, improving microcirculation, and anti-inflammation. It can be used in research on Bell's palsy.

AEG40826 (HGS1029), a second mitochondria-derived activator of caspases (SMAC) mimetic, is an inhibitor of apoptosis (IAP) inhibitor. AEG40826 degrades cellular IAP1 (cIAP1) and blocks TNF-α pro-survival signaling. AEG40826 can be used for cancer research.

ADP receptor-IN-1 (compound 21) is a platelet ADP receptor inhibitor. ADP receptor-IN-1 shows both IC50 values <10 μM at a platelet ADP receptor binding assay and aggregation using a platelet-rich plasma assay.

Adipic acid monoethyl ester is a PROTAC linker that can be used in the synthesis of PROTACs.

Adenosine receptor antagonist 7 is an orally active triple A1/A2A/A2B adenosine receptor antagonist with Ki values of 1.5, 0.6 and 21 nM. Adenosine receptor antagonist 7 shows potent inhibitory activity (IC50 = 0.8 nM) of cAMP production in A2AR-HEK293 cells. Adenosine receptor antagonist 7 can enhance infiltration of effector T cells and increase the CD8+/Treg ratio companied with Avelumab. Adenosine receptor antagonist 7can be used for the research of cancer, such as colon cancer.